CN103864892A - 肽酪氨酸酶抑制剂及其应用 - Google Patents

肽酪氨酸酶抑制剂及其应用 Download PDF

Info

Publication number
CN103864892A
CN103864892A CN201410043510.7A CN201410043510A CN103864892A CN 103864892 A CN103864892 A CN 103864892A CN 201410043510 A CN201410043510 A CN 201410043510A CN 103864892 A CN103864892 A CN 103864892A
Authority
CN
China
Prior art keywords
peptide
skin
tyrosinase
amino acid
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410043510.7A
Other languages
English (en)
Chinese (zh)
Inventor
巴锡尔·M·汉塔什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN103864892A publication Critical patent/CN103864892A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201410043510.7A 2007-06-27 2008-06-25 肽酪氨酸酶抑制剂及其应用 Pending CN103864892A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93733107P 2007-06-27 2007-06-27
US60/937,331 2007-06-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200880105015.7A Division CN101795703B (zh) 2007-06-27 2008-06-25 肽酪氨酸酶抑制剂及其应用

Publications (1)

Publication Number Publication Date
CN103864892A true CN103864892A (zh) 2014-06-18

Family

ID=40186023

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880105015.7A Active CN101795703B (zh) 2007-06-27 2008-06-25 肽酪氨酸酶抑制剂及其应用
CN201410043510.7A Pending CN103864892A (zh) 2007-06-27 2008-06-25 肽酪氨酸酶抑制剂及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN200880105015.7A Active CN101795703B (zh) 2007-06-27 2008-06-25 肽酪氨酸酶抑制剂及其应用

Country Status (7)

Country Link
US (2) US8026208B2 (enExample)
EP (1) EP2180897B1 (enExample)
JP (2) JP5568008B2 (enExample)
KR (1) KR101507188B1 (enExample)
CN (2) CN101795703B (enExample)
CA (1) CA2728140C (enExample)
WO (1) WO2009003037A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109689676A (zh) * 2016-09-15 2019-04-26 帝斯曼知识产权资产管理有限公司 新型化合物

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641591B1 (en) 1999-08-26 2003-11-04 John H. Shadduck Instruments and techniques for controlled removal of epidermal layers
US8048089B2 (en) 2005-12-30 2011-11-01 Edge Systems Corporation Apparatus and methods for treating the skin
US10172644B2 (en) 2006-03-29 2019-01-08 Edge Systems Llc Devices, systems and methods for treating the skin
US9566088B2 (en) 2006-03-29 2017-02-14 Edge Systems Llc Devices, systems and methods for treating the skin
US8343116B2 (en) 2008-01-04 2013-01-01 Edge Systems Corporation Apparatus and method for treating the skin
GB0612669D0 (en) * 2006-06-27 2006-08-09 Univ Leeds Biomarkers for preeclampsia
CN101795703B (zh) * 2007-06-27 2015-05-06 里兰斯坦福初级大学理事会 肽酪氨酸酶抑制剂及其应用
US8814836B2 (en) * 2008-01-29 2014-08-26 Edge Systems Llc Devices, systems and methods for treating the skin using time-release substances
WO2009097451A1 (en) 2008-01-29 2009-08-06 Edge Systems Corporation Apparatus and method for treating the skin
US8999916B2 (en) 2010-03-31 2015-04-07 Agency For Science, Technology And Research Crosslinked peptide hydrogels
US9687591B2 (en) 2010-03-31 2017-06-27 Agency For Science, Technology And Research Building stratified biomimetic tissues and organs using crosslinked ultrashort peptide hydrogel membranes
ES2574056T3 (es) 2010-03-31 2016-06-14 Agency For Science, Technology And Research Péptido/peptoide anfifílico lineal e hidrogel que comprende el mismo
WO2011154639A2 (fr) * 2010-06-11 2011-12-15 Galderma Research & Development Modulateurs de edn3 et/ou ednrb dans le traitement du melasma
WO2011154640A2 (fr) * 2010-06-11 2011-12-15 Galderma Research & Development Modulateurs de trmp1, mmp2, mia ou ptgs1 dans le traitement du melasma
US9320698B2 (en) * 2011-05-11 2016-04-26 Escape Therapeutics, Inc. Peptide tyrosinase inhibitors and uses thereof
JP6026765B2 (ja) * 2012-04-24 2016-11-16 花王株式会社 チロシナーゼ阻害剤
WO2014116187A1 (en) * 2013-01-28 2014-07-31 Agency For Science, Technology And Research Crosslinked peptide hydrogels
US10238812B2 (en) 2013-03-15 2019-03-26 Edge Systems Llc Skin treatment systems and methods using needles
EP3903704B1 (en) 2013-03-15 2022-11-02 HydraFacial LLC Devices and systems for treating the skin
EP4324414A3 (en) 2014-12-23 2024-05-01 HydraFacial LLC Devices and methods for treating the skin using a rollerball or a wicking member
US10179229B2 (en) 2014-12-23 2019-01-15 Edge Systems Llc Devices and methods for treating the skin using a porous member
KR20240014104A (ko) 2015-07-08 2024-01-31 하이드라페이셜 엘엘씨 모발 성장을 촉진하기 위한 디바이스, 시스템 및 방법
KR101895906B1 (ko) * 2016-07-07 2018-10-04 주식회사 한국화장품제조 펩타이드 리포좀을 포함하는 스틱형 화장료 조성물
US11045493B2 (en) 2016-07-11 2021-06-29 The Regents Of The University Of California Synthetic melanin nanoparticles and uses thereof
EA202091213A1 (ru) 2017-11-14 2020-08-13 Юнилевер Н.В. Пептиды для повышения содержания меланина в меланоцитах
CA3084853A1 (en) 2017-12-06 2019-06-13 Unilever Plc A skin darkening composition
CN109180785B (zh) * 2018-11-08 2021-08-20 中国科学院上海应用物理研究所 一种具有抑制黑色素生成和抗紫外线损伤作用的美白还原多肽及其应用
WO2021087076A1 (en) * 2019-10-30 2021-05-06 Northwestern University Selenium-containing analogues of pheomelanin and related materials and methods of making
US11291474B2 (en) 2020-01-06 2022-04-05 Ed F. Nicolas Skin treatment tool applicator tip
KR20220140750A (ko) * 2020-02-13 2022-10-18 이스케이프 테라퓨틱스, 인코퍼레이티드 흑색종 치료제
KR102506020B1 (ko) * 2020-11-27 2023-03-06 웰펩 주식회사 항산화 활성 및 티로시나제 저해활성을 갖는 펩타이드 및 이를 포함하는 조성물
USD1065551S1 (en) 2021-09-10 2025-03-04 Hydrafacial Llc Skin treatment device
USD1016615S1 (en) 2021-09-10 2024-03-05 Hydrafacial Llc Container for a skin treatment device
USD1042807S1 (en) 2021-10-11 2024-09-17 Hydrafacial Llc Skin treatment tip
US12377036B2 (en) 2022-06-21 2025-08-05 Northwestern University Melanin hair dye with thickeners
USD1084369S1 (en) 2023-02-10 2025-07-15 Hydrafacial Llc Skin treatment tip
CN117106016A (zh) * 2023-09-01 2023-11-24 海南大学 阿胶源酪氨酸酶抑制肽及其应用
CN117106015B (zh) * 2023-09-01 2024-04-26 海南大学 一种椰子源活性肽及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
US3978427A (en) 1973-06-15 1976-08-31 American Optical Corporation Erbium laser device having non-masking laser rod holders
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB2103622B (en) * 1981-06-16 1986-01-15 Genentech Inc Production of foot and mouth disease vaccine from microbially expressed antigens
US4421769A (en) 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
EP0389950A1 (en) 1989-03-23 1990-10-03 Lion Corporation Melanocyte-stimulating hormone inhibitor and external preparation containing the same
US5773291A (en) 1989-04-26 1998-06-30 Sloan-Kettering Institute For Cancer Research Non-melanotytic mammalian cell constitutively expressing biologically active human tyrosinase and use thereof
WO1991004019A1 (en) * 1989-09-12 1991-04-04 The Regents Of The University Of California Therapeutic peptides and proteins
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
WO1992013958A1 (en) 1991-02-06 1992-08-20 Georgetown University Receptor blocking peptides of fibroblast growth factor receptor
US5688768A (en) * 1991-02-19 1997-11-18 Cor Therapeutics, Inc. Recombinant thrombin receptor and related pharmaceuticals
US5256766A (en) * 1991-02-19 1993-10-26 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
EP1160322A3 (en) 1992-08-21 2002-01-02 Wa Pharm AB Human melanocyte stimulating hormone receptors
US5670483A (en) * 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5455228A (en) 1993-07-02 1995-10-03 The Research Foundation Of State University Of New York Peptidase resistant thrombin receptor peptide ligand
US5603933A (en) * 1993-08-31 1997-02-18 Board Of Regents, The University Of Texas CD4 peptides for binding to viral envelope proteins
US5589460A (en) 1994-05-04 1996-12-31 Innapharma, Inc. Tri-, tetra-, penta-, and polypeptides and their therapeutic use as an antidepressant agent
CN1179105A (zh) * 1995-01-17 1998-04-15 小马克·奎伦 α－促黑激素拮抗剂及相关方法
US6602856B1 (en) 1995-01-17 2003-08-05 J. Mark Quillan Antagonists of alpha-melanocyte stimulating hormone and methods based thereon
US6319498B1 (en) 1995-03-14 2001-11-20 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
WO1996040033A1 (en) * 1995-06-07 1996-12-19 Clarion Pharmaceuticals Inc. Non-biological patch for hemostasis
ATE405664T1 (de) 1996-03-28 2008-09-15 Univ Boston Methoden zur modulation der melaninsynthese
US6143723A (en) 1996-05-20 2000-11-07 Ramaiah; Abburi Pigmentory agent
KR100478928B1 (ko) 1996-11-08 2005-08-18 세이렌가부시끼가이샤 세리신또는세리신가수분해물을유효성분으로하는비의약용항산화제,화장품,식품변색방지제,음식물,심근경색치료제,동맥경화치료제,당뇨병치료제,암치료제,또는뇌줄중치료제
US6982249B1 (en) 1997-04-23 2006-01-03 The Regents Of The University Of Michigan Bradykinin analogs as selective inhibitors of cell activation
US6368877B1 (en) * 1997-06-25 2002-04-09 Massachusetts Institute Of Technology Self-assembling peptide surfaces for cell patterning and interactions
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US6323219B1 (en) * 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US20020034772A1 (en) 1999-06-29 2002-03-21 Orlow Seth J. Methods and compositions that affect melanogenesis
US7083781B2 (en) 1999-08-19 2006-08-01 Lavipharm S.A. Film forming polymers, methods of use, and devices and applications thereof
CA2412011A1 (en) 2000-06-16 2001-12-27 Hercules Incorporated Chemically-modified antimicrobial peptides, compositions and methods of production and use
US7449180B2 (en) * 2001-02-06 2008-11-11 John Kisiday Macroscopic scaffold containing amphiphilic peptides encapsulating cells
WO2002062969A2 (en) * 2001-02-06 2002-08-15 Massachusetts Institute Of Technology Cellular reprogramming in peptide hydrogel and uses thereof
US20020182237A1 (en) 2001-03-22 2002-12-05 The Procter & Gamble Company Skin care compositions containing a sugar amine
US20020192738A1 (en) 2001-04-27 2002-12-19 Janice Brissette Tyrosinase assay
US7658742B2 (en) 2001-11-21 2010-02-09 Envy Medical, Inc. Skin treatment system and method of use
US6695853B2 (en) 2001-11-21 2004-02-24 Emed, Inc. Microdermabrasion system and method of use
US6649150B2 (en) 2002-04-11 2003-11-18 Em Industries Skin-lightening
US7025957B2 (en) 2002-09-06 2006-04-11 Desert Whale Jojoba Company Composition and method to whiten skin
US7125572B2 (en) 2004-05-14 2006-10-24 Kaoder Industry Company, Ltd. Tyrosinase inhibitor extract
US20090202989A1 (en) 2005-06-28 2009-08-13 Hillan Kenneth J Egfr and kras mutations
JP4742365B2 (ja) * 2005-10-04 2011-08-10 独立行政法人産業技術総合研究所 チロシナーゼ阻害剤、美白剤および美白外用剤
CN101795703B (zh) * 2007-06-27 2015-05-06 里兰斯坦福初级大学理事会 肽酪氨酸酶抑制剂及其应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109689676A (zh) * 2016-09-15 2019-04-26 帝斯曼知识产权资产管理有限公司 新型化合物
CN109689676B (zh) * 2016-09-15 2022-10-18 帝斯曼知识产权资产管理有限公司 新型化合物

Also Published As

Publication number Publication date
KR20100039861A (ko) 2010-04-16
CN101795703B (zh) 2015-05-06
CN101795703A (zh) 2010-08-04
CA2728140C (en) 2019-09-03
JP5568008B2 (ja) 2014-08-06
CA2728140A1 (en) 2008-12-31
EP2180897B1 (en) 2019-05-08
EP2180897A1 (en) 2010-05-05
KR101507188B1 (ko) 2015-03-30
US8026208B2 (en) 2011-09-27
US20110293709A1 (en) 2011-12-01
JP2014193163A (ja) 2014-10-09
JP2010531892A (ja) 2010-09-30
US8338364B2 (en) 2012-12-25
US20090099093A1 (en) 2009-04-16
EP2180897A4 (en) 2015-08-26
WO2009003037A1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
CN103864892A (zh) 肽酪氨酸酶抑制剂及其应用
CN101795702B (zh) 寡肽酪氨酸酶抑制剂及其应用
ES2421262T3 (es) Composición para el cuidado personal y cosmética que contiene tetrapéptidos con las unidades CX1X2G, PX1X2P o PX1X2K
US9567368B2 (en) Peptide tyrosinase activators
JP2024075684A (ja) 皮膚症状を改善するためのポリペプチドおよび方法
BR112017013696B1 (pt) Método para diminuir o aparecimento de sinais dermatológicos do envelhecimento
KR20170135442A (ko) 두피의 건강 개선을 위한 화장료 조성물 및 이의 제조방법
US9320698B2 (en) Peptide tyrosinase inhibitors and uses thereof
JP7695716B2 (ja) 化粧品および医薬品に使用するためのペプチドおよび組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140618